Aims Patients with atrial fibrillation who despite taking oral anti-coagulant therapy (OAT)
suffer a stroke or systemic embolism (SSE) without vascular cause or who develop left atrial …

Left atrial appendage occlusion is not inferior to oral anticoagulants in the prevention of
stroke in several randomized controlled trials. However, the clinical efficacy and safety …

Background Peridevice leak (PDL) is a limitation of left atrial appendage occlusion.
Objectives The aim of this study was to assess the incidence of and outcomes associated …

Aims Atrial fibrillation (AF) and chronic kidney disease (CKD) often coexist and share an
increased risk of thrombo-embolism (TE). CKD concomitantly predisposes towards a pro …

Background Long-term oral anticoagulation is the mainstay therapy for thromboembolic (TE)
prevention in patients with atrial fibrillation. However, left atrial appendage occlusion (LAAO) …

Background Left atrial appendage occlusion (LAAO) is an alternative to oral anticoagulation
(OAC) to decrease the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF); …

Abstract Purpose of Review Left atrial appendage closure (LAAC) has shown to be non-
inferior to oral anticoagulation (OAC) for non-valvular atrial fibrillation (AF). LAAC is now …

Although oral anticoagulants (OACs) are first-line therapy for stroke prevention in patients
with atrial fibrillation (AF), some patients cannot be treated with OACs due to absolute or …

Background Pivotal trials of percutaneous left atrial appendage closure (LAAC) used
dedicated post-procedure antithrombotic protocols. However, there is no consensus on the …

Introduction The Watchman FLX is a novel device for transcatheter left atrial appendage
occlusion (LAAO) specifically designed to improve procedural performance in more complex …